Abstract
Despite effective frontline therapies, many patients (pts) with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) eventually relapse and require additional therapies to control their disease. Duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor, was approved by the FDA for the treatment of relapsed or refractory (R/R) CLL or SLL after ≥2 prior therapies. Here we present the efficacy
and safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).
and safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).
Original language | English |
---|---|
Pages (from-to) | 116-117 |
Number of pages | 2 |
Journal | Leukemia and Lymphoma |
Volume | 61 |
Issue number | S1 |
DOIs | |
Publication status | Published - 21 May 2020 |
Event | XVIII International Workshop on Chronic Lymphocytic Leukemia - EICC: Edinburgh International Conference Centre, Edinburgh, United Kingdom Duration: 20 Sept 2019 → 23 Sept 2019 https://www.iwcll2019.org/ (Conference website) |
Keywords
- Duvelisib
- chronic lymphocytic leukemia
- small lymphocytic lymphoma
- Prior therapy
- inhibitor
- relapse prevention